收费全文 | 7520篇 |
免费 | 373篇 |
国内免费 | 36篇 |
耳鼻咽喉 | 101篇 |
儿科学 | 475篇 |
妇产科学 | 105篇 |
基础医学 | 908篇 |
口腔科学 | 133篇 |
临床医学 | 451篇 |
内科学 | 1525篇 |
皮肤病学 | 125篇 |
神经病学 | 450篇 |
特种医学 | 143篇 |
外国民族医学 | 1篇 |
外科学 | 1272篇 |
综合类 | 220篇 |
一般理论 | 5篇 |
预防医学 | 456篇 |
眼科学 | 171篇 |
药学 | 774篇 |
中国医学 | 36篇 |
肿瘤学 | 578篇 |
2023年 | 60篇 |
2022年 | 66篇 |
2021年 | 277篇 |
2020年 | 181篇 |
2019年 | 222篇 |
2018年 | 268篇 |
2017年 | 176篇 |
2016年 | 241篇 |
2015年 | 262篇 |
2014年 | 355篇 |
2013年 | 406篇 |
2012年 | 615篇 |
2011年 | 604篇 |
2010年 | 341篇 |
2009年 | 271篇 |
2008年 | 459篇 |
2007年 | 426篇 |
2006年 | 422篇 |
2005年 | 366篇 |
2004年 | 298篇 |
2003年 | 284篇 |
2002年 | 194篇 |
2001年 | 118篇 |
2000年 | 116篇 |
1999年 | 104篇 |
1998年 | 56篇 |
1997年 | 32篇 |
1996年 | 24篇 |
1995年 | 27篇 |
1994年 | 26篇 |
1993年 | 31篇 |
1992年 | 62篇 |
1991年 | 41篇 |
1990年 | 35篇 |
1989年 | 61篇 |
1988年 | 48篇 |
1987年 | 23篇 |
1986年 | 32篇 |
1985年 | 33篇 |
1984年 | 26篇 |
1983年 | 37篇 |
1981年 | 13篇 |
1980年 | 19篇 |
1979年 | 24篇 |
1978年 | 14篇 |
1975年 | 11篇 |
1973年 | 18篇 |
1972年 | 13篇 |
1971年 | 12篇 |
1970年 | 13篇 |
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献Background
Multiple myeloma (MM) is a hematologic malignancy of plasma cell origin. MM primarily affects bone marrow, but extramedullary sites can also be involved. Myelomatous pleural effusion (MPE) is an atypical and rare complication of MM. We aimed to systematically study the incidence and clinicopathologic profile of patients with MPE in a real-world setting.Patients and Methods
In this retrospective study, 415 consecutive patients with MM managed at a tertiary care center in North India during a study period of January 1, 2010 to December 31, 2015 were evaluated for MPE. The patients with MPE were analyzed for their clinical profile, diagnosis, treatment, and outcomes.Results
Of these 415 patients, 11 (2.65%) patients had MPE. The median age of the study population was 50 years with male preponderance. The majority of these patients had immunoglobin (Ig)G Kappa disease. All patients had higher than International Staging System stage I disease. MPE was a presenting feature at MM diagnosis in 45.45% (n = 5) of the patients, whereas the rest developed MPE during follow-up. MPE presented predominantly (81.8%) as a unilateral effusion. Concurrent extramedullary involvement at other site was seen in 45.45% (n = 5), with 3 (27%) patients having concurrent myelomatous ascites. Six of these were managed aggressively, whereas 5 patients opted for palliation. The outcomes were dismal (90.9% mortality), with a median survival of 2.47 months.Conclusion
MPE is a rare entity, and positive outcomes of therapy remain low with dismal prognosis. 相似文献To find out the relative prevalence of fetal neural tube defect (NTD) and its outcome in terms of survival at birth and beyond 2 years of age.
MethodsA 10-year prospective (2008–2018) observational study was performed, which included all prenatally detected fetal NTD. Two-year follow-up was done in cases of pregnancies resulting in live birth, in terms of their survival, physical morbidity and developmental delay.
ResultsNTD was seen in 401/648 (62%) cases among the central nervous system malformations. More than half of the cases (54.1%) presented after 20 weeks of gestation, and 42.8% of the mothers were primiparous. Spina bifida was seen in 206 cases, anencephaly in 144, encephalocele in 43, whereas iniencephaly was seen in only eight cases. Associated anomalies were present in 51.2%. Only 19.0% cases were live-born, and merely 11% were alive beyond 2 years of age. Among types of spina bifida, lumbosacral meningomyocele was the most common (41.6%), whereas thoracic was the rarest (8.7%). After 2 years, physical disability was observed in more than half of the cases who survived.
ConclusionsNTD is one of the commonest malformations with high mortality, and the physical and mental sub-normality is high among those who survive.
相似文献